We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 24

The enforcement heat increases and Stryker is just the latest

  • Faegre Baker Daniels
  • -
  • USA
  • -
  • October 30 2009

Recent statements by FDA and DOJ officials, including FDA Commissioner Hamburg, promised an increase in enforcement

New Jersey Consumer Fraud Act

  • Day Pitney LLP
  • -
  • USA
  • -
  • September 13 2013

In a business-friendly decision, Perez v. Professionally Green, LLC, 214 N.J. ___ (2013), a unanimous New Jersey Supreme Court held yesterday that a

Matrixx Securities fraud case could affect product liability law

  • Squire Sanders
  • -
  • USA
  • -
  • December 10 2010

Sometimes the most significant changes in the law come from unexpected places

Indictment of former GlaxoSmithKline in-house attorney highlights risks and provides lessons for handling document requests in government investigations

  • Jenner & Block
  • -
  • USA
  • -
  • November 23 2010

A former in-house counsel at pharmaceutical company GlaxoSmithKline ("GSK"), Lauren Stevens, was indicted earlier this month for obstruction of a proceeding, false statements, and falsifying or concealing documents for her role in responding to a document request from the Food and Drug Administration ("FDA"

EU political update 22 - 26 July 2013

  • Clifford Chance LLP
  • -
  • European Union
  • -
  • July 26 2013

On 17 July, the European Commission set out certain proposals aiming to improve Union-wide prosecution of criminals who defraud European Union

British man imprisoned in ‘Operation Singapore’ investigation

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • May 3 2011

The UK MHRA's 'Operation Singapore' investigation into the infiltration of counterfeit medicine into the UK's supply chain during five months in 2007 has concluded with a British man being sentenced to eight years imprisonment

FDA to increase enforcement actions against corporate officials

  • Faegre Baker Daniels
  • -
  • USA
  • -
  • March 5 2010

Corporate executives have rarely been personal targets of FDA enforcement actions

Conclusory allegations won't cut it under the False Claims Act

  • Quarles & Brady LLP
  • -
  • USA
  • -
  • August 29 2013

The Fifth Circuit dismissed a qui tam relator's claims under the False Claims Act ("FCA") regarding allegedly defective devices sold to the

Even without knowledge or participation, corporate officers can be criminally liable for subordinates' misdeeds

  • Fox Rothschild LLP
  • -
  • USA
  • -
  • July 30 2012

The Food and Drug Administration and the U.S. Court of Appeals for the D.C. Circuit’s treatment of former Purdue Pharma executives is a reminder to executives and in-house counsel, particularly those in regulated industries, that they can face criminal liability and career-ending debarment for their company’s conduct, even if the executives did not personally participate in the conduct or even know about it

Seventh Circuit dismisses securities class action for failure to plead fraud

  • Holland & Knight LLP
  • -
  • USA
  • -
  • June 18 2012

On May 21, 2012, the United States Court of Appeals for the Seventh Circuit dismissed a federal securities class action against a medical device manufacturer